Human Recombinant Growth Factors and Their Effect on Vaginal Microbiota Modulation in Menopause Patients

¹Department of Obstetrics & Gynecology, Hospital Universitario San Jorge, Colombia

²Department of Gynecology, La Cardio, Bogotá DC, Colombia

*Corresponding author: Pablo González-Isaza, MD, Department of Obstetrics & Gynecology, Hospital Universitario San Jorge, Cra. 4 # 24-88, Pereira, Risaralda, Colombia, Phone: 320.788.7509, ORCID: 0000-0001-7798-5141; Email: [email protected]

Received Date: December 09, 2024

Publication Date: December 20, 2024

Citation: González-Isaza P, et al. (2024). Human Recombinant Growth Factors and Their Effect on Vaginal Microbiota Modulation in Menopause Patients. Dermis. 4(5):26.

Copyright: González-Isaza P, et al. © (2024).

ABSTRACT

Genitourinary syndrome of menopause (GSM) is a normal consequence of aging, hormonal deprivation, or cancer treatments, it is estimated to affect approximately 1 out of 2 women. Management of symptoms has limited benefit. Restoration of a healthy vaginal microbiome may be an ideal avenue for management of GSM. The purpose of this study was to evaluate the effect of a novel topical formulation of human recombinant growth factors on vaginal microbiota modulation in menopause patients. A prospective single center longitudinal study included 37 voluntary patients with symptoms related to GSM and dysbiosis, such as vaginal discharge and odor. A home-based regimen of human recombinant growth factors was used by patients twice a week, up to follow up at six months. Evaluations included validated questionnaires, punch biopsies and vaginal swabs performed at baseline, and at the end of the study period. Vaginal flora modulation and normal pH were achieved by the end of the treatment protocol. Topical human recombinant growth factors to modulate vaginal microbiota are a viable alternative therapy for GSM.

Keywords: Menopause, Genitourinary Syndrome of Menopause, Vaginal Microbiota, Vaginal Microbiome, Growth Factors